News Daily News Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective Michael O'Riordan February 23, 2024
News Daily News Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval Todd Neale May 04, 2018
News Daily News Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond Shelley Wood December 26, 2017
News Daily News FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors Michael O'Riordan August 18, 2016